Disease relevance of Buflomedil

• Therapeutic trials with buflomedil in patients with peripheral vascular diseases have shown that it increases walking distances in those with intermittent claudication and heals trophic lesions and reduces rest pain in many patients with more severe vasculopathies [1].
• Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases [1].
• Anaphylactic reactions to buflomedil [2].
• In acute pancreatic fistula rats, buflomedil, CRL40634 and CRL40598 did not suppress the inhibitory effect of clonidine against 2-deoxy-glucose-induced pancreatic secretion [3].
• The purpose of the study was to examine the effects of buflomedil hydrochloride (BFL) on the expression of adhesion molecules (beta2-integrins) and oxygen radical production of circulating and emigrated intra-abdominal polymorphonuclear leukocytes (PMNL) in a standardized porcine model of hyperdynamic endotoxemia [4].

Psychiatry related information on Buflomedil

• The pharmacological effects of buflomedil in patients with multi-cerebral infarcts dementia: an open, preliminary assessment [5].
• In conclusion, buflomedil is as effective or more effective than dihydrogenated ergot alkaloids in the treatment of senile dementia associated with cerebrovascular insufficiency and could prove a valuable addition to long-term therapy if further studies support the trend shown in this study [6].
• Psychometric investigations demonstrated that after 50 mg buflomedil i.v. there was a significant improvement as compared with placebo in cognitive function based on the Pauli test as well as an increase in correct reactions in the alphabetical reaction test [7].
• The efficacy of buflomedil was monitored using rating scales and neuropsychological tests [8].
• Compared with placebo, buflomedil showed a clear superiority with regard to improvement in cognitive dysfunction and psychosomatic dysfunction, with a trend toward statistical significance in improvement in interpersonal relations [9].

High impact information on Buflomedil

• METHODS: The physiological response to a 15 min balloon occlusion of the left anterior descending coronary artery followed by 1 h of reperfusion was monitored in 17 placebo treated dogs and compared with that of 15 dogs which received 10 mg.kg-1 of buflomedil [10].
• Pretreatment with buflomedil enhances ventricular function by reducing the dysfunctional area after transient coronary artery occlusion [10].
• OBJECTIVE: The aim was to evaluate whether buflomedil (a drug used to treat peripheral vascular disease and which has a number of pharmacological actions potentially beneficial to dysfunctional myocardium) would preserve myocardial function after transient coronary artery occlusion followed by reperfusion [10].
• Buflomedil concentrations in blood and viscera in a case of fatal intoxication [11].
• 1. Blood flow (measured by radio-labelled microspheres), fibre composition and capillary/fibre ratio were estimated in rat fast twitch skeletal muscles (tibialis anterior and extensor digitorum longus) five weeks after unilateral ligation of the common iliac artery in animals treated with either saline, torbafylline, pentoxifylline or buflomedil [12].

Chemical compound and disease context of Buflomedil

• According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication [13].

Biological context of Buflomedil

• The results showed that buflomedil feeding did not alter the systolic blood pressure of either spontaneous hypertensive rats or normal rats [14].
• The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration [15].
• Because such activity of buflomedil consists of enhancement of physiologic mechanisms of vasodilation and tissue protection occurring in the course of ischemic events, new pharmacologic perspectives for the drug may arise [16].
• We have evaluated the effect of buflomedil on blood viscosity in insulin-dependent diabetic patients [17].
• An evaluation of the ability of the peripheral vasodilator buflomedil to improve vascular patency after acute frostbite [18].

Anatomical context of Buflomedil

• Effects of buflomedil on the responsiveness of canine vascular smooth muscle [19].
• The presence of adrenergic nerve endings appear to augment the postjunctional inhibitory effects of buflomedil [19].
• Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment [20].
• The haemodynamic and haemorheological effects of buflomedil after acute intravenous infusion and after chronic treatment were studied in 25 patients with occlusive arterial diseases of the lower limbs [21].
• In contrast, continuous oral administration of buflomedil (30 mg/kg x 7 days) to rats had no significant effect on the specific bindings of [3H]SCH23390, [3H]spiperone, [3H]apomorphine and [3H]QNB to synaptic membrane preparations obtained from the striatum [22].

Associations of Buflomedil with other chemical compounds

• The augmentation by buflomedil of the release of [3H]norepinephrine evoked by electrical stimulation was prevented by phentolamine [19].
• Determination of buflomedil hydrochloride [2',4',6'-trimethoxy-4-(pyrrolidinyl)butyrophenone hydrochloride] by reversed-phase ion-pair high-performance liquid chromatography [23].
• The vascular effects of buflomedil were studied by retinal fluorescein angiography carried out before (control) and after the intravenous infusion of buflomedil (250 mg in 15 min) in patients with different pathological conditions of retinal circulation [24].
• Using in vitro models of cell adhesion, buflomedil decreased 100% of histamine related neutrophil adhesion (flow system) and partially inhibited adhesion after IL-1-4 hours (flow and stable systems) [25].
• In addition, both L-glutamic acid decarboxylase activity (GAD) and gamma-aminobutyric acid (GABA) content showed a significant decrease in the substantia nigra following a single administration of buflomedil [26].

Gene context of Buflomedil

• The activity of three enzymes was measured (acetylcholinesterase - Ache, dehydrogenase glucoso-6-phosphate - G-6-PD and gluthatione reductase - GR) for both bfl and TCDD-treated RBC [27].
• Buflomedil (except at supra-therapeutic concentrations) exerted no effect on endothelin release by HUVECS [28].
• Experience with buflomedil in peripheral arterial occlusive disease [29].
• In vitro incubation of PRP with buflomedil in concentrations above 10 mumol/l resulted in a significant depression of PA to approximately one-third of the control [30].
• Buflomedil dosage was elevated to 6.3 mg/l (N = 4-4.5 mg/l) [31].

Analytical, diagnostic and therapeutic context of Buflomedil

• However, at 30 min after reperfusion, ejection fraction was 89% of normal in the buflomedil group compared with 69% of normal in the placebo group (p < 0.03) [10].
• Analysis of buflomedil in mouse, rat and rabbit plasma by reversed-phase ion-pair high-performance liquid chromatography [32].
• Buflomedil hypochloride improves the capillary perfusion in such related situations, evoking a possible effect upon neutrophils [25].
• Buflomedil is a potent interfering substance in immunoassays of tricyclic antidepressants [33].
• The meta-analysis results were based on "effect size", a standardized difference in mean response between buflomedil and placebo [34].

References